A B S T R A C T DLB (dementia with Lewy bodies) is a syndrome associated with underlying LBD (Lewy body disease), with manifestations in the cognitive, neuropsychiatric, motor, sleep and autonomic domains. The variable symptomatology and complex array of neuronal involvement and neurotransmitter deficiencies make the diagnosis and management of patients with DLB challenging. The genetic underpinnings of DLB have only recently begun to unfold. In this review, the clinical features, diagnostic criteria, genetics and treatment issues relating to DLB will be discussed, in which a comprehensive approach to the diagnosis and management is emphasized.
INTRODUCTION
Friederich Lewy in the early 1900s first identified the intraneuronal inclusions in the substantia nigra of patients with PD (Parkinson's disease). These inclusions were subsequently coined 'LBs (Lewy bodies)', and were henceforth considered the defining neuropathological feature of PD. Okazaki et al. [1] first described LBs in the cerebral cortex in patients with dementia in 1961. Few reports on LB cortical pathology occurred over the subsequent several years, perhaps due in part to the challenge of identifying LBs on standard haematoxylin/eosin-stained cortical regions. In the 1980s, ubiquitin immunocytochemistry allowed easier recognition of LBs [2, 3] , but structures other than LBs also stained with ubiquitin. α-Synuclein immunocytochemistry was developed in the late 1990s, permitting easy identification of LBs and LNs (Lewy neurites) [4, 5] . Interest in LB dementia [now termed DLB (dementia with LBs)] and LBD (LB disease) has led to hundreds of publications from groups of investigators globally.
In this review, the terminology surrounding DLB and LBD, the clinical features of DLB, current diagnostic criteria for DLB and LBD, genetics of DLB and PD with dementia, and management strategies of DLB will be considered.
TERMINOLOGY
The terminology used in the characterization of LBD and clinical syndromes associated with LBD continue to evolve. Most experts now use the term LBD to refer to the histopathological disorder, but other terms include diffuse LBD, cortical LBD and the LB variant of Alzheimer's disease. Although few would argue about which clinical features constitute PD or the term PD itself, labels for the syndrome with prominent cognitive and neuropsychiatrical features associated with LBD include diffuse LBD, cortical LBD, LB dementia, the LB variant of Alzheimer's disease and senile dementia of the Lewy type. The overlap in the clinical and pathological terms has fostered much confusion. Consensus criteria for the clinical and neuropathological diagnoses were published in 1996 by the CDLB (Consortium on DLB), which suggested that the syndrome of 'DLB' should be used, and the neuropathological disorder be termed 'LBD' [6] . Therefore most experts restrict the term DLB to be used
Figure 1 Schematic diagram of the '1 year rule'
Diagnosis of DLB applies to those who meet criteria for DLB [6] and develop parkinsonism at any time after the onset of dementia (upper panel) or develop dementia no more than 1 year after the onset of parkinsonism (middle panel). The term PDD refers to those patients who develop dementia more than 1 year after the onset of parkinsonism (lower panel).
only for the clinical syndrome, and the term LBD, but not DLB, is used when characterizing autopsied material.
Debate continues on how to label patients who have typical features of PD who subsequently develop dementia. Currently, most apply the label DLB to all patients who develop parkinsonism after the onset of dementia and also to those who develop dementia within 1 year from the onset of parkinsonism (Figure 1 ). The term PDD (PD with dementia) refers to those patients who develop dementia more than 1 year after the onset of parkinsonism (Figure 1) . No consensus exists yet on the criteria required for the diagnosis of PDD, but the features of 'dementia due to PD' have been described in DSM-IV-TR ® (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision) [7] . Controversy continues on the so-called '1 year rule' for differentiating DLB from PDD ( Figure 1 ). Although the clinical features, management and neuropathological substrates for DLB and PDD are now appreciated to be similar, if not identical, most agree that the '1 year rule' should remain in place from the research perspective, primarily so that the differential expression of parkinsonism and dementia in LBD can be studied further.
CLINICAL FEATURES
In LBD, LBs, LNs and neuronal loss tend to be widespread, involving the medulla to the neocortex as well as the peripheral autonomic nervous system. Clinical symptomatology is therefore also wide, with most features falling into one of five categories: cognitive impairment, neuropsychiatric features, motor dysfunction, sleep disorders and autonomic dysfunction [6, [8] [9] [10] [11] [12] [13] [14] [15] [16] (Table 1) .
Cognitive impairment
In contrast with Alzheimer's disease, in which anterograde memory dysfunction and then language dysfunction typically evolves, the domains of attention/ concentration, executive functioning and visuospatial functioning are the most consistent domains impaired in DLB [17] . Patients tend to complain of forgetfulness but, based on neuropsychological studies, this may represent dysfunction in frontosubcortical neural networks more than mesial temporal lobes. Problems with performing sequential tasks, for example, ordering from a menu, using remote controls, navigating in familiar surroundings and lying in the correct orientation in a bed, are typical symptoms. On examination in the office setting, patients tend to do poorly on attention (performing simple calculations, serial subtraction and digit span), learning (requiring several trials to learn short word lists) and constructional praxis (drawing the intersecting pentagons, clocks or cubes). Many also complain of losing one's train of thought or having difficulty verbalizing simple words or phrases, which some have termed 'verbal blocking', and this is often readily apparent during interviews in [6, 8, 9 ], but they remain rather nebulous and poorly operationalized. Fluctuations refer to periods of time when cognition and arousal are clearly abnormal contrasting with other periods with normal or near-normal functioning. Sleep/wake abnormalities [18] and neurochemical alterations [11] have been proposed as substrates for fluctuations.
Neuropsychiatric features
Recurrent and fully formed visual hallucinations are another defining feature of DLB [6, 8, 19] . In most patients, hallucinations begin during nocturnal hours in dimmed lighting, which is typically the bedroom. Over time, hallucinations tend to occur during the day and night independently of the surroundings and intensity of ambient light. The perceived images are usually insects, animals or people, and sometimes these are frightening. Arguing between patients and relatives often ensue after concerns over images in the home or yard are verbalized and, since these images are so vivid, patients often cannot be convinced that the images are truly not present. Visual illusions are also common in which patients perceive objects differently from the their true identity (e.g. a chair appearing to be a dog). In fact visual illusions and hallucinations often coincide, suggesting a common or overlapping neural basis. Paranoid delusions occur with some frequency as well [19] . An uncommon but striking phenomenon known as the Capgras' syndrome can also occur in which the patient believes that a relative or friend (usually spouse) has been replaced by an identicalappearing imposter [20] .
Depression is also common in DLB and may appear years before the onset of dementia [6, 19] . Other features include anxiety, hallucinations in other sensory modalities, agitation/aggressive behaviour and hypomania.
Motor dysfunction
Spontaneous parkinsonism (i.e. unrelated to dopamine antagonist exposure) is another core feature of DLB [6, 8, 9] . The manifestations of typical PD-masked facies, stooped posture, shuffling gait, difficulty with fine motor skills, sialorrhea, tremor and bradykinesia, all may occur [21] , although tremor tends to be more symmetric and related to posture/action. Postural instability can be profound early in the illness. Myoclonus, which may cause confusion with Creutzfeldt-Jakob disease, can also occur. Dopaminergic dysfunction is believed to be at the root of most of these motor manifestations.
Sleep disorders
The primary sleep disorders associated with DLB include RBD (REM sleep behaviour disorder), insomnia, OSA (obstructive sleep apnoea), central sleep apnoea, restless legs syndrome and periodic limb movement in sleep [22] . In one polysomnographic series of DLB patients, at least one sleep disorder was present in almost every case [23] . Excessive daytime somnolence is also common in which patients will struggle to stay awake through the day [22] . These sleep disorders are important to recognize, as effective treatments exist for them all.
RBD deserves further comment. RBD is a parasomnia manifested by dream-enactment behaviour in which patients will scream, swear, flail their limbs, punch, kick and lunge out of bed [14, 15, [24] [25] [26] [27] . The dreams tend to have a nightmarish quality, with a remarkable tendency for the dreams to have a chasing or attacking theme. The patient is very rarely the perpetrator; he/she is usually protecting himself/herself against aggressors. If the patient is awakened in the midst of a dream (which is unwise for bed partners to do, since their attempts at awakening the patient may be interwoven into the dream and lead to injury), the content of the dream mirrors what has just been exhibited. Broken bones and subdural haematomas have been reported in patients, and bed partners have endured bruises, lacerations and pulled hair. RBD often begins years or even decades before any cognitive or motor symptoms develop and, therefore, RBD may be the first sign of an evolving neurodegenerative disorder in many individuals [14, 15, [24] [25] [26] [27] . RBD is common in DLB (as well as PD without or with dementia and multiple system atrophy) [13] [14] [15] [16] 22, [27] [28] [29] [30] [31] . Since RBD is frequent in DLB and almost non-existent in Alzheimer's disease and frontotemporal dementia, some have argued that RBD co-existing with dementia is diagnostic of DLB, even in the absence of parkinsonism and visual hallucinations [31] , and RBD should be considered a core feature of DLB [32, 33] . The presence of RBD may carry more weight in the updated criteria for the diagnosis of DLB.
Autonomic dysfunction
LBs, LNs and neuronal loss have been identified in the intermediolateral column of the spinal cord as well as the sympathetic nerves in the thoracic (particularly in and around the heart) and abdominal (particularly Auerbach's and Meissner's plexi) structures [34, 35] . This widespread involvement would explain the frequent and sometimes disabling features of autonomic dysfunction, namely OH (orthostatic hypotension), impotence, urinary incontinence and constipation [34, 36, 37] . Although the frequency of each feature in DLB has not been studied systematically, there are treatments available for some, particularly OH and constipation.
DIAGNOSTIC CRITERIA
The criteria for the clinical diagnosis of DLB as per the CDLB (or 'McKeith criteria') were originally published in 1996 [6] (Table 2) . Although there were data questioning the accuracy of these criteria [38] , little was changed following the second meeting of this consortium in 1999 [8] . More recent clinicopathological analyses have shown considerable variability among groups of investigators [39] [40] [41] [42] [43] The First and Second Reports of the CDLB suggested ubiquitin immunohistochemistry be used to characterize autopsied brain tissue, and required neuropathologists to count LBs in specific brain regions. This allowed categorization of brains as being brainstem-, limbic-or neocortical-predominant LBD. Since 1999, α-synuclein immunohistochemistry has been identified as superior to anti-ubiquitin immunostaining, and semiquantitative assessment of the frequency of LBs has been recommended. Hence there will be revisions to the neuropathological processing, evaluation and interpretation in the Third Report of the CDLB.
GENETICS OF DLB AND PDD PHENOTYPES OF LBD
Familial PD has long been recognized, with the study of the genetic underpinnings of familial PD being pioneered by many investigators, and several excellent reviews on the genetics of familial PD have been published [44] [45] [46] . Some of the PD patients described in these reports developed dementia, many of which would now be labelled as PDD. Familial DLB has recently been noted. The following review will focus on dementia without and with parkinsonism in which at least one autopsied affected relative has been found to have LBD.
Data on the reports published to date on familial DLB/PDD are shown in Table 3 ; the reports are presented sequentially under each genetic cause (if known) to allow discussion of how the identification of the genetic underpinnings has been unravelled. A large kindred from the Contursi region of Italy (i.e., 'Contursi kindred') with familial PD was characterized [47] . Although none of the patients described in this report were noted to have dementia, limbic LBs were present in one case. Polymeropolous et al. [48] linked the disease in this family to chromosome 4 and soon thereafter a mutation (E53T) in α-synuclein (encoded by SNCA) was identified in this and other kindreds of Italian and Greek origin [49] . One such family included patients who developed l-dopa-responsive parkinsonism in their 40s and then dementia, along with several other features such as excessive daytime somnolence, OH, urinary incontinence, myoclonus and paranoia [50] . Marked degeneration in the CA2 and CA3 subfields of the hippocampus was present in two autopsied cases [50] . An A30P mutation in the protein encoded by SNCA was identified in a kindred from Germany [51] . Although dementia is not specifically stated as present in any of these cases, neuropsychological testing revealed mild-to-severe impairment in one or more cognitive domains; no patient from this family has undergone autopsy as yet [51, 52] . More recently, a report of a kindred with parkinsonism (typically l-dopa-responsive, onset in late 40s to mid-60s) followed by dementia associated with an E46K mutation in the protein encoded by SNCA was published, with LBs present throughout the brain of the single autopsied case [53] . Hence most individuals with mutations in SNCA have exhibited typical features of PD, with some subsequently developing dementia.
The large kindred reported by Spellman [54] , Waters and Miller [55] and Muenter et al. [56] (now termed the 'Iowa kindred') also exhibited l-dopa-responsive PD, often followed by dementia and widespread LBD, as well as CA2/CA3 degeneration, have been found at autopsy. This family was linked to chromosome 4, but no mutation was identified in SNCA despite multiple analyses, which was indeed perplexing. Further studies with FISH (fluorescent in situ hybridization) revealed that triplication of normal SNCA on one chromosome plus the normal single SNCA on the other chromosome (i.e. four copies of SNCA compared with the normal two) [57] . Subsequent analyses in other familial PD kindreds have revealed SNCA duplications (i.e. three copies total of SNCA) [58, 59] , but dementia has not been reported in any of these affected individuals. These findings have important implications. First, overproduction of α-synuclein appears to cause a neurodegenerative disease associated with LBs and LNs, analogous with the overproduction of β-amyloid in Down's syndrome and development of Alzheimer's disease. Secondly, there appears to be a dose effect, with SNCA duplications associated with PD, and SNCA triplication associated with PDD [60] . Yet LBs in limbic with or without neocortical structures are often present in non-demented PD patients [61] . The mechanism by which overproduction of α-synuclein causes differential involvement of the nervous system, and hence phenotypic variability, remains to be elucidated. However, the evolution of PD to PDD would be consistent with the staging system of sporadic PD proposed by Braak et al. [62, 63] in which α-synuclein involvement follows a caudal-rostral direction of progression.
As shown in Table 3 , many other kindreds with familial PDD have been reported, and no genetic cause has been identified [64] [65] [66] [67] . Those with dementia and either a SNCA mutation or triplication had significant CA2/ CA3 degeneration, suggesting that this finding in any case with LBD may suggest a genetically mediated disorder. Many kindreds with familial DLB (Table 3) have also been identified recently, and no genetic alteration has been found in any of these [68] [69] [70] [71] [72] . Most of the autopsied familial DLB cases have had some degree of Alzheimer pathology, which may account in part for the cognitive and neuropsychiatric presentation of these cases. Clearly other genes involved in LB pathogenesis have yet to be discovered, and the association between LBD and Alzheimer's disease must be disentangled. The mechanism of nervous system affliction is probably different in the DLB cases, however, with more involvement of limbic and neocortical structures and perhaps a rostral-caudal direction of progression.
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been identified very recently to cause familial parkinsonism [73, 74] . No case of a primary dementia syndrome has been identified yet with an LRRK2 mutation, but the gene has only recently been discovered, and it is very large and subsequent analyses may uncover such a phenotype. This gene may encode processes upstream in the cascade of events involved in neurodegeneration, since autopsied cases have shown strikingly variable findings, with α-synuclein-positive pathology, tau-positive pathology or pathology with no distinctive features present in affected individuals [75] .
MANAGEMENT
Symptomatic therapy for the various clinical manifestations exist, but no therapy has yet been identified Table 3 Clinical, neuropathological and genetic findings in families with dementia without or with parkinsonism associated with LBD in at least one affected relative Abbreviations: A, amygdale; AH, auditory hallucinations; B, brainstem; Degen, degeneration; CA2,3 Degen, degeneration of the CA2 and CA3 hippocampal subfields; Cog onset, age of onset of cognitive decline; D, dementia; Del, delusion; Dys, dystonia; EDS, excessive daytime somnolence; F, female; Fluc., fluctuations in cognition or arousal; L, limbic; + LDR, positive L-dopa response; − LDR, no L-dopa response; M, male; MCI, mild cognitive impairment; My, myoclonus; N, neocortical; NFT, neurofibrillary tangles; NP, neuritic plaques; NMS, neuroleptic malignant syndrome; NS, not specified; P, parkinsonism; P + CI, parkinsonism plus cognitive impairment (but not dementia); Paran, paranoia; path, pathological; Park onset, age of onset of parkinsonism; prDLB, clinically probable DLD; psDLB, clinically possible DLB; SNCA, α-synuclein gene; Synd, syndrome; UI, urinary incontinence; VH onset, age of onset of visual hallucinations; VSNGP, vertical supranuclear gaze palsy; 0, feature absent or not specified; +, feature present. [4, 5] . Importantly, since the severity of neuronal loss appears to be less in DLB than that in Alzheimer's disease and other dementias [4, 5, 76, 77] , DLB cases can respond more frequently and more dramatically to drug therapy than in other disorders. The remainder of this review documents the established or potential treatments for DLB-related symptomatology.
Cognitive impairment
Cognition and functional abilities can improve with cholinesterase inhibitor therapy [78] . The response is modest in most, but dramatic in some. The cholinesterase inhibitors used most often in clinical practice include donepezil, rivastigmine and galantamine. Rivastigmine is the only agent in this class that has been proven to be effective and safe in DLB in a double-blind placebocontrolled trial [79] , but small series and open trials have suggested efficacy with the other agents. It is unclear if any one agent is better than the others in DLB. There are no published studies on the efficacy and safety of memantine, psychostimulants or dopaminergic agents in DLB patients. Clinical experience indicates that some may improve with one or more of these drugs, but response is highly variable and difficult to predict.
Neuropsychiatric features
Visual hallucinations are often the most troubling neuropsychiatric feature in DLB, and they do not always require drug treatment if they are not frightening. The cholinesterase inhibitors, atypical antipsychotics and psychostimulants can be considered for management of hallucinations, delusions and apathy [79] [80] [81] [82] . The following atypical antipsychotics can be considered: clozapine [83] [84] [85] , risperidone [86, 87] , olanzapine [88, 89] and quetiapine [85, 90] . A phenomenon known as 'neuroleptic sensitivity' can occur with exposure to even small doses of haloperidol, chlorpromazine and other conventional neuroleptics, and these agents are now strongly discouraged [91] . All of the atypical neuroleptics can cause orthostatism, so home blood pressure monitoring may be necessary in select patients. Depression is very common in DLB and certainly warrants treatment. The SSRIs (selective serotonin reuptake inhibitors), such as fluoxetine, paroxetine, citalopram and escitalopram, and SNRIs [selective noradrenaline (norepinephrine) re-uptake inhibitors], such as venlafaxine, mirtazepine and buproprion, can be used. Anxiety can respond to the SSRIs and SNRIs, buspirone and cholinesterase inhibitors. The anticholinergic properties of the tricyclic antidepressants and paroxetine make these unattractive in the treatment of DLB. ECT (electroconvulsive therapy) may be appropriate for select patients [92] .
Motor dysfunction
Clinicians must decide what degree of parkinsonism is acceptable compared with what should be treated, as dopaminergic agents can worsen psychotic symptoms, hypersomnolence and orthostatism. l-dopa was recently shown to be well-tolerated in most, but only a third experienced significant improvement in parkinsonism [93] . Dopamine agonists are generally poorly tolerated in DLB patients. Most experts view dementia as an exclusionary criterion for pallidotomy and deep brain stimulation and thus are not appropriate for DLB subjects.
Autonomic dysfunction
OH and constipation are arguably the most pervasive autonomic manifestation of LBD. Elevating the head of the bed to avoid 'pressure naturesis', liberalizing fluid intake as well as salt in the diet, salt tablets, thigh-high compression stockings, fludrocortisone and midodrine are all potential treatments for OH. The cholinesterase inhibitors may improve OH [94] , although this has not been rigorously studied in DLB subjects. Strategies for managing constipation include increased water intake, increased fibre, a variety of laxative formulations and mosapride [95] .
Sleep disorders

RBD
Some patients with moderate-to-severe OSA can exhibit dream enactment behaviour identical with those with RBD. Clonazepam, the most effective agent for RBD, can worsen OSA, so most patients should undergo polysomnography with or without nasal CPAP (continuous positive airway pressure) trial if there is a history suggesting RBD and/or OSA.
Since the dreams associated with RBD are usually unpleasant, one goal of therapy is to reduce or eliminate nightmares. Serious injuries can occur to patients and bed partners, thus the more prominent goal of therapy for RBD are to minimize the abnormal behaviour [14, 22] . Moving lamps and furniture away from the bed and placing cushions on the floor beside the bed are simple ways to minimize injury. When drug therapy is appropriate, clonazepam (usually effective at 0.25-1.0 mg/ night [14, 22, 25, 26] ), melatonin (usually effective at 3-12 mg/night either as monotherapy or in conjunction with clonazepam [96] ) or quetiapine (usually effective at 25-100 mg/night [14, 22] ) are warranted.
Insomnia
When attempting to manage insomnia, one first must sort out if this is due to one or more primary sleep disorders (e.g. restless legs syndrome, periodic limb movement in sleep, OSA or central sleep apnoea syndrome), by depression, by a circadian dysrhythmia or by medication [22] . If no clear cause can be identified, polysomnography may be appropriate. If the findings are most consistent with idiopathic or psychophysiological insomnia, agents to consider include trazodone, chloral hydrate, zolpidem, zaleplon and the atypical neuroleptics (e.g. quetiapine, olanzapine, clozapine or risperidone). Melatonin may be effective in some patients. GHB (γ -hydroxybutyrate) and eszopiclone have not been studied yet in DLB.
Excessive daytime somnolence
One can approach excessive daytime somnolence similarly to insomnia, taking into account primary sleep disorders, depression, circadian dysrhythmia and effects of medication. Some may require polysomnography without or with MSLT (multiple sleep latency tests) to adequately evaluate the cause(s) [22] . There is evidence suggesting a narcolepsy-like state may explain hypersomnolence and hallucinations in patients with PD [97] , and similar phenomena could be occurring in DLB patients [14, 15] . The narcoleptic-like state may be important therapeutically in which psychostimulants could potentially improve hallucinations and delusions in patients with DLB, and experience has shown efficacy of modafinil and methylphenidate [14] .
FUTURE DIRECTIONS
DLB is a fascinating but debilitating syndrome associated with LBD, with manifestations in the cognitive, neuropsychiatric, motor, sleep and autonomic domains. Comprehensive assessment and selected pharmacotherapy can lead to improvement in symptoms and avoidance of older agents that may cause harm. The genetic underpinnings of DLB and PDD as well as PD, including alterations in SNCA and LRRK2 and undoubtedly other genes, will offer insights into pathogenesis. Although basic scientists investigate these and other issues, clinicians will need to identify early markers of disease and assess longitudinal changes in the multitude of manifestations to design clinical trials appropriately. The obvious hope is that agents effective in slowing down progression or halting or preventing disease altogether may someday be developed.
